New study tracks heart risks of prostate cancer combo in japanese men
NCT ID NCT06010914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study is collecting data from Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. The main goal is to track heart-related side effects and other safety issues in real-world settings. No extra tests or visits are required—just routine care data. The study runs from 2023 to 2026.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide
What this could lead to
If successful, this study could provide real-world safety information to support the use of darolutamide in combination with ADT and docetaxel for Japanese men with metastatic hormone-sensitive prostate cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. It only collects data from routine care, and results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, Japan